SG Americas Securities LLC Buys 23,968 Shares of 10x Genomics $TXG

SG Americas Securities LLC boosted its stake in 10x Genomics (NASDAQ:TXG) by 60.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 63,767 shares of the company’s stock after purchasing an additional 23,968 shares during the quarter. SG Americas Securities LLC’s holdings in 10x Genomics were worth $1,040,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. AQR Capital Management LLC grew its stake in 10x Genomics by 241.3% in the second quarter. AQR Capital Management LLC now owns 4,137,801 shares of the company’s stock valued at $47,916,000 after acquiring an additional 2,925,372 shares during the period. Millennium Management LLC grew its stake in 10x Genomics by 84.7% in the third quarter. Millennium Management LLC now owns 5,437,969 shares of the company’s stock valued at $63,570,000 after acquiring an additional 2,494,142 shares during the period. Wellington Management Group LLP grew its stake in 10x Genomics by 126.6% in the third quarter. Wellington Management Group LLP now owns 4,285,628 shares of the company’s stock valued at $50,099,000 after acquiring an additional 2,394,355 shares during the period. Quantinno Capital Management LP grew its stake in 10x Genomics by 207.2% in the second quarter. Quantinno Capital Management LP now owns 2,233,526 shares of the company’s stock valued at $25,864,000 after acquiring an additional 1,506,530 shares during the period. Finally, Blue Water Life Science Advisors LP acquired a new position in 10x Genomics in the second quarter valued at about $12,746,000. Institutional investors own 84.68% of the company’s stock.

Insider Transactions at 10x Genomics

In other news, insider Benjamin J. Hindson sold 7,826 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $18.58, for a total transaction of $145,407.08. Following the completion of the transaction, the insider directly owned 424,779 shares of the company’s stock, valued at $7,892,393.82. This represents a 1.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Adam Taich sold 8,968 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $18.58, for a total value of $166,625.44. Following the transaction, the chief financial officer directly owned 288,417 shares of the company’s stock, valued at $5,358,787.86. This represents a 3.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 41,426 shares of company stock valued at $779,895 over the last three months. Company insiders own 9.39% of the company’s stock.

Wall Street Analysts Forecast Growth

TXG has been the subject of a number of research analyst reports. Citigroup boosted their target price on 10x Genomics from $18.00 to $24.00 and gave the company a “neutral” rating in a research note on Tuesday. Deutsche Bank Aktiengesellschaft set a $17.00 target price on 10x Genomics and gave the company a “hold” rating in a research note on Friday, February 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of 10x Genomics in a research note on Friday, March 27th. Bank of America set a $21.00 target price on 10x Genomics in a research note on Monday, January 12th. Finally, UBS Group boosted their target price on 10x Genomics from $14.00 to $20.00 and gave the company a “neutral” rating in a research note on Friday, February 20th. Five analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $18.89.

10x Genomics Price Performance

TXG stock opened at $23.02 on Thursday. The stock has a market capitalization of $2.94 billion, a P/E ratio of -65.77 and a beta of 2.17. The business has a 50-day moving average of $19.97 and a 200-day moving average of $17.44. 10x Genomics has a fifty-two week low of $6.94 and a fifty-two week high of $23.65.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Thursday, February 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.06. The company had revenue of $166.03 million during the quarter, compared to analysts’ expectations of $160.35 million. 10x Genomics had a negative return on equity of 6.89% and a negative net margin of 6.77%.10x Genomics’s revenue for the quarter was up .6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.40) earnings per share. Equities analysts expect that 10x Genomics will post -1.43 EPS for the current year.

10x Genomics Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.